PARIS & MILAN--(BUSINESS WIRE)--Acticor Biotech SAS and Mediolanum farmaceutici S.p.A., today announced that they have entered into a research collaboration agreement for Acticor’s project ACT-017, a humanized antibody Fragment (Fab). Under the terms of the agreement, Mediolanum will co-finance research and development of ACT-017, currently in preclinical development as a potential next generation antithrombotic treatment for acute ischemic stroke.
Under the terms of the agreement, Acticor received an undisclosed nonrefundable lump sum payment for the preclinical development of ACT-017 and is eligible for additional payments to launch clinical development phases I and II. Mediolanum will co-own the results of the collaboration and will acquire marketing rights over two main European countries.
“This agreement further confirms Mediolanum’s strong commitment to identify novel treatments for important underserved medical conditions, such as ACT-017” commented its founder and President, Mr. Rinaldo Del Bono.
“We are excited about this great opportunity. ACT-017 has shown great potential in preclinical development and will be a strong addition to our growing pipeline” added Alessandro Del Bono, CEO of Mediolanum.
Acticor Biotech’s CEO Gilles Avenard stated: “This agreement validates and strengthens our development strategy for ACT-017. We have made excellent progress in our development program and are very proud to be partnering with Mediolanum, an important player in the European pharmaceutical industry.”
About Ischemic stroke - http://acticor-biotech.com/en/stroke/
About Acticor Biotech - http://acticor-biotech.com/en/
About ACT-017, the therapeutic candidate - http://acticor-biotech.com/en/technology/
About Mediolanum farmaceutici - http://www.mediolanum-farma.it/en/index.html